INT112082

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 1.89
Pain Relevance 0.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (Vsig2) biological_process (Vsig2)
Anatomy Link Frequency
articular 1
femur 1
urine 1
knee 1
Vsig2 (Mus musculus)
Pain Link Frequency Relevance Heat
Intracerebroventricular 1 100.00 Very High Very High Very High
intrathecal 1 100.00 Very High Very High Very High
antinociception 5 97.24 Very High Very High Very High
antagonist 9 88.28 High High
tail-flick 4 88.24 High High
imagery 29 83.16 Quite High
Osteoarthritis 251 79.20 Quite High
Pain 19 61.00 Quite High
Neurotransmitter 14 56.64 Quite High
Adalimumab 4 50.00 Quite Low
Disease Link Frequency Relevance Heat
Vibrio Infection 2 100.00 Very High Very High Very High
Bordatella Infection 2 99.76 Very High Very High Very High
Hypercalcemia 39 96.96 Very High Very High Very High
Toxicity 32 92.80 High High
Poisoning 217 85.52 High High
Increased Venous Pressure Under Development 41 79.28 Quite High
Osteoarthritis 210 79.20 Quite High
Stress 6 75.00 Quite High
Disease 83 68.56 Quite High
Pain 17 61.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effects of intracerebroventricular (i.c.v.) and intrathecal (i.t.) 3-isobutyl-1-methylxanthine (IBMX), cholera toxin (CTX) and pertussis toxin (PTX) administration on immobilization-induced antinociception were studied in ICR mice.
Regulation (effects) of CTX associated with antinociception, bordatella infection, vibrio infection, intracerebroventricular and intrathecal
1) Confidence 0.40 Published 2003 Journal Eur Neuropsychopharmacol Section Abstract Doc Link 12888188 Disease Relevance 0.48 Pain Relevance 0.51
For instance, based upon the evaluation of CTX content in fish samples using a mouse bioassay, an MPL of 0.01 ng g?
Regulation (evaluation) of CTX
2) Confidence 0.25 Published 2010 Journal Marine Drugs Section Body Doc Link PMC2901828 Disease Relevance 0.39 Pain Relevance 0
Therefore, the processing parameters identified for the preparation of this formulation were used for the preparation of microspheres for both the animal trial (ATM) and the clinical trial (CTM) microsphere batches.


Regulation (microspheres) of CTM
3) Confidence 0.06 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
-CTX GVIA as well as W7 and L-NAME, but was not affected by apamin or nifedipine.
Neg (not) Regulation (affected) of CTX
4) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2659787 Disease Relevance 0.14 Pain Relevance 0.29
The concentration of creatinine was measured using a commercially available colorimetric kit (METRA™ QUIDEL Corp., San Diego, CA), and uCTX2 values were corrected for urine creatinine concentration (mmol/L).
Regulation (values) of uCTX2 in urine
5) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2840035 Disease Relevance 0.15 Pain Relevance 0.04
The low dose of the SERM showed intermediate effects on CTX-II levels.
Regulation (effects) of CTX-II
6) Confidence 0.01 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC400436 Disease Relevance 0.17 Pain Relevance 0
Significant correlations were found between 4-week changes in CTX-II levels and final measurements of cartilage surface erosion (total knee) in study cohorts B and C (r = 0.74 and 0.50 respectively).
Regulation (changes) of CTX-II in knee
7) Confidence 0.01 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC400436 Disease Relevance 0.08 Pain Relevance 0
There was a high correlation between changes in CTX-II observed in the first 4 weeks of the study period and subsequent erosion of articular knee cartilage.
Regulation (changes) of CTX-II in articular
8) Confidence 0.01 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC400436 Disease Relevance 0.13 Pain Relevance 0.03
When the four compartments of the knee were considered individually, the highest correlations were observed for the medial femur (in which the highest surface erosion was seen), where significant correlation with both absolute levels and changes in CTX-II was found in all study cohorts (Table 3).
Regulation (changes) of CTX-II in femur
9) Confidence 0.01 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC400436 Disease Relevance 0.06 Pain Relevance 0
All rats from this cohort were stratified in quartiles according to the magnitude of change in CTX-II levels, and the average surface erosion in each quartile was calculated.
Regulation (change) of CTX-II
10) Confidence 0.01 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC400436 Disease Relevance 0.06 Pain Relevance 0
Changes in CTX-II and MMP-3 at 12 weeks correlated significantly with changes in BASDAI (r=0.31 and 0.33), and CRP (r=0.40 and 0.43) (p<or=0.005).
Regulation (Changes) of CTX-II
11) Confidence 0.01 Published 2008 Journal J. Rheumatol. Section Body Doc Link 18785308 Disease Relevance 0.05 Pain Relevance 0
Change in CTX-II at 12 weeks also correlated significantly with change in MMP-3 (r=0.41; p<0.0001).
Regulation (Change) of CTX-II
12) Confidence 0.01 Published 2008 Journal J. Rheumatol. Section Body Doc Link 18785308 Disease Relevance 0 Pain Relevance 0
At 1 year, CTX-II and NTX-I values in the placebo group were significantly higher than those in the risedronate 15-mg group (14.5% ± 5.4 and 17.2% ± 4.9 higher, respectively).
Regulation (values) of CTX-II
13) Confidence 0.00 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1174954 Disease Relevance 0.20 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox